Market
Highlights:
Fibromyalgia
syndrome co-exists with other painful conditions, such as migraine and other
types of headaches, temporomandibular joint disorders, irritable bowel syndrome
(IBS), and interstitial cystitis. The treatment of fibromyalgia includes both
targeted and symptomatic approach. Till date, there are only three FDA approved
drugs for the fibromyalgia treatment, i.e., Lyrica (PFIZER), Cymbalta (Eli
Lilly and Company), and Savella (Allergan plc). However, there are few other
drugs prescribed by physicians to control the symptoms of fibromyalgia such as
pain relievers, muscle relaxants, and traditional Chinese medicine.
Growing
geriatric population, increasing cases of rheumatic diseases, growing awareness
among the population, and rising incidences of traumatic stress and road
accidents are the key factors driving the Chinese fibromyalgia market.
According to a study published in the Arthritis Care & Research journal in
2017, fibromyalgia and related symptoms worsen the functional status of
individuals with rheumatoid arthritis. Around 15%-30% of patients with
rheumatic disorders have co-morbid fibromyalgia syndrome.
However,
difficulty in diagnosis of the disease, and stringent FDA regulations may
hinder the growth of the market to an extent. As fibromyalgia syndrome is
associated with other chronic diseases so, its diagnosis takes a long time. As
fibromyalgia syndrome is associated with other chronic diseases so, its
diagnosis takes a long time. According to a study published in Arthritis
Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart
disease in fibromyalgia patients was 47% higher than the general population.
Key
Players
Some
of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca,
Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services,
Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc.,
Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT,
NOVARTIS, and others.
Regional
Analysis
South
Central China accounted for the major share of the market owing to the rising
prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic
diseases are also capable of fuelling the fibromyalgia market in China.
Prevalence of rheumatoid arthritis is around 0.35%, with the significantly
higher rate in Northern China as compared to the Southern part.
The
rising healthcare expenditure is also propelling the growth of the market. In
China, the total expenditure on health per capita in 2014 was USD 731, as per
the World Health Organization (WHO) in 2015. The health expenditure in China
grew at a rate of 11.6% per year, suggested by a study published in BMC Health
Services Research journal in 2017. This rate is much faster than the growth of
the country’s economy, i.e., 9.9% per year.
Access
Report Details @ https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630
Segmentation
The
Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment,
and end-user.
On
the basis of the diagnosis, the market is classified into laboratory evaluation
and presence of central sensitization.
On
the basis of the treatment, the market is segmented into targeted treatment and
symptomatic treatment.
On the basis of the end-users, the market is
segmented into hospitals, clinics, diagnostic centers, and others.
No comments:
Post a Comment